English
B2M Knockout iPS Cell Line
B2M Knockout iPS Cell Line
Artikelnummer
BPS82161
Verpackungseinheit
1 vial
Hersteller
BPS Bioscience
Verfügbarkeit:
wird geladen...
Preis wird geladen...
Products from BPS Bioscience require a minimum order value above 400€
Applications: Assess the role of B2M knockout in iPS cell biology and differentiation.Assess the impact of B2M knockout in cell therapy research and development.
Background: The discovery by Yamanaka and colleagues in 2007 that 4 factors were sufficient to reprogram terminally differentiated fibroblasts into pluripotent stem cells launched the advent of human induced pluripotent stem (iPS) cell technology. These human iPS cells are capable of both self-renewal and differentiation down all three germline lineages and provide both a tool to model human development and disease in the relevant differentiated human cell types, and a unique opportunity for high throughput drug screening and cell therapy development.B2M (Beta-2-Microglobulin) forms a heteromeric complex with HLA-A, HLA-B and HLA-C molecules to generate the functional Class I MHC molecule responsible for antigen presentation to T-Cells. Class I MHC molecules are present on the surface of all nucleated cells and play a role in the rejection of organs or allogenic cells during organ transplantation and cell therapy. B2M is an attractive target to reduce the immunogenicity of iPS cell-derived allogenic cell therapies.
Description: The B2M Knockout iPS Cell Line is an iPS cell line that has been edited using CRISPR/Cas9 technology to delete B2M (Beta-2-Microglobulin) gene expression. The B2M-targeting CRISPR/Cas9 editing agents were delivered via transduction with B2M (Human) CRISPR/Cas9 Lentivirus (Non-Integrating) (BPS Bioscience #78341).
Host Cell Line: Non-Disease Human iPS Cell Line (iXCells 30HU-002)
Mycoplasma Testing: The cell line has been screened to confirm the absence of Mycoplasma species.
Storage Stability: Cells are shipped in dry ice and should immediately be thawed or stored in liquid nitrogen upon receipt. Do not use a -80°C freezer for long term storage. Contact technical support at support@bpsbioscience.com if the cells are not frozen in dry ice upon arrival.
Supplied As: Each vial contains 2 x 106 cells in 1 ml of iPS Cell Freezing Medium
Warnings: Avoid freeze/thaw cycles
Biosafety Level: BSL-1
References: Cong L., et al., 2013 Science. 339(6121):819-23.
Gerace D., et al., 2023 Cell Reports Medicine 4: 100879
Jinek M., et al., 2012 Science. 337(6096):816-21.
Mali P., et al., 2013 Science. 339(6121):823-6.
Lanza R., et al., 2019 Nat Rev Immunol 19: 723-733.
Takahashi K., et al., 2007 Cell. 131(5):861-872.
Yang L., et al., 2013 Nucleic Acids Res. 41(19):9049-61
Applications: Assess the role of B2M knockout in iPS cell biology and differentiation.Assess the impact of B2M knockout in cell therapy research and development.
Background: The discovery by Yamanaka and colleagues in 2007 that 4 factors were sufficient to reprogram terminally differentiated fibroblasts into pluripotent stem cells launched the advent of human induced pluripotent stem (iPS) cell technology. These human iPS cells are capable of both self-renewal and differentiation down all three germline lineages and provide both a tool to model human development and disease in the relevant differentiated human cell types, and a unique opportunity for high throughput drug screening and cell therapy development.B2M (Beta-2-Microglobulin) forms a heteromeric complex with HLA-A, HLA-B and HLA-C molecules to generate the functional Class I MHC molecule responsible for antigen presentation to T-Cells. Class I MHC molecules are present on the surface of all nucleated cells and play a role in the rejection of organs or allogenic cells during organ transplantation and cell therapy. B2M is an attractive target to reduce the immunogenicity of iPS cell-derived allogenic cell therapies.
Description: The B2M Knockout iPS Cell Line is an iPS cell line that has been edited using CRISPR/Cas9 technology to delete B2M (Beta-2-Microglobulin) gene expression. The B2M-targeting CRISPR/Cas9 editing agents were delivered via transduction with B2M (Human) CRISPR/Cas9 Lentivirus (Non-Integrating) (BPS Bioscience #78341).
Host Cell Line: Non-Disease Human iPS Cell Line (iXCells 30HU-002)
Mycoplasma Testing: The cell line has been screened to confirm the absence of Mycoplasma species.
Storage Stability: Cells are shipped in dry ice and should immediately be thawed or stored in liquid nitrogen upon receipt. Do not use a -80°C freezer for long term storage. Contact technical support at support@bpsbioscience.com if the cells are not frozen in dry ice upon arrival.
Supplied As: Each vial contains 2 x 106 cells in 1 ml of iPS Cell Freezing Medium
Warnings: Avoid freeze/thaw cycles
Biosafety Level: BSL-1
References: Cong L., et al., 2013 Science. 339(6121):819-23.
Gerace D., et al., 2023 Cell Reports Medicine 4: 100879
Jinek M., et al., 2012 Science. 337(6096):816-21.
Mali P., et al., 2013 Science. 339(6121):823-6.
Lanza R., et al., 2019 Nat Rev Immunol 19: 723-733.
Takahashi K., et al., 2007 Cell. 131(5):861-872.
Yang L., et al., 2013 Nucleic Acids Res. 41(19):9049-61
| Artikelnummer | BPS82161 |
|---|---|
| Hersteller | BPS Bioscience |
| Hersteller Artikelnummer | 82161 |
| Verpackungseinheit | 1 vial |
| Mengeneinheit | STK |
| Wirt | Human |
| Produktinformation (PDF) | Download |
| MSDS (PDF) |
|
Verwandte Artikel
Markieren Sie die Artikel, um Sie dem Warenkorb hinzuzufügen oder
Immer für Sie da
Gernot Ensinger, M.Sc.
Laurent Haze
